About: In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2
Creator	Lina, Bruno Padey, Blandine Pizzorno, Andrés Rosa-Calatrava, Manuel Terrier, Olivier Dubois, Julia Julien, Thomas Traversier, Aurélien Brun, Pauline Dulière, Victoria Traversier,
Source	Elsevier; Medline; PMC
abstract	In response to the current pandemic caused by the novel SARS-CoV-2, identifying and validating effective therapeutic strategies is more than ever necessary. We evaluated the in vitro antiviral activities of a shortlist of compounds, known for their cellular broad-spectrum activities, together with drugs that are currently under evaluation in clinical trials for COVID-19 patients. We report the antiviral effect of remdesivir, lopinavir, chloroquine, umifenovir, berberine and cyclosporine A in Vero E6 cells model of SARS-CoV-2 infection, with estimated 50% inhibitory concentrations of 0.99, 5.2, 1.38, 3.5, 10.6 and 3 μM, respectively. Virus-directed plus host-directed drug combinations were also investigated. We report a strong antagonism between remdesivir and berberine, in contrast with remdesivir/diltiazem, for which we describe high levels of synergy, with mean Loewe synergy scores of 12 and peak values above 50. Combination of host-directed drugs with direct acting antivirals underscore further validation in more physiological models, yet they open up interesting avenues for the treatment of COVID-19.
has issue date	2020-07-15(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2020.104878
bibo:pmid	32679055
has license	no-cc
sha1sum (hex)	323d5b60b38bafb11d83660d7a40b717c0bba193
schema:url	https://doi.org/10.1016/j.antiviral.2020.104878
resource representing a document's title	In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2
has PubMed Central identifier	PMC7361110
has PubMed identifier	32679055
schema:publication	Antiviral Res
resource representing a document's body	covid:323d5b60b38bafb11d83660d7a40b717c0bba193#body_text
is schema:about of	named entity 'evaluation' named entity 'combined' named entity 'ROSA' named entity 'CITE' named entity 'IN VITRO' named entity 'In vitro' named entity 'activity' named entity 'Lina' named entity 'antiviral activity' named entity 'infection' named entity '5.2' named entity 'remdesivir' named entity 'diltiazem' named entity 'high levels' named entity '3.5' named entity 'antiviral' named entity 'cyclosporine' named entity 'berberine' named entity 'SARS-CoV-2' named entity 'host-directed' named entity 'remdesivir' named entity 'Vero E6' named entity 'antiviral effect' named entity 'remdesivir' named entity 'lopinavir' named entity '10.6' named entity 'dose-response' named entity 'chloroquine' named entity 'clinical trials' named entity 'SARS-CoV-2' named entity 'remdesivir' named entity 'SARS-CoV-2' named entity 'therapeutic strategies' named entity 'umifenovir' named entity 'berberine' named entity 'berberine' named entity 'remdesivir' named entity 'cite' named entity 'antiviral activity' named entity 'doi' named entity 'Antiviral Research' named entity 'SARS-CoV-2' named entity 'antiviral activity' named entity 'EVALUATION' named entity 'SARS-COV-2' named entity 'DRUGS' named entity 'TITLE' named entity 'SARS-CoV-2' named entity 'https' named entity 'doi' named entity 'Please' named entity 'evaluation' named entity 'antiviral' named entity 'SARS-CoV-2' named entity 'activity' named entity 'SINGLE' named entity 'COMBINED' named entity 'Title' named entity 'antiviral' named entity 'In vitro' named entity 'ANTIVIRAL' named entity 'LINA' named entity 'SARS-CoV-2' named entity 'HTTPS' named entity 'BRUN' named entity 'DUBOIS' named entity 'EVALUATION' named entity 'JULIEN' named entity 'SARS-COV-2' named entity 'TERRIER' named entity 'RESEARCH'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software